Glaxo to develop microRNA drugs with Regulus

04/17/2008 | Forbes

Regulus Therapeutics LLC and GlaxoSmithKline have entered into a deal worth up to $600 million to develop new microRNA treatments for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus, a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, sees the deal as an important development in its efforts in microRNA therapeutics, president and CEO Kleanthis Xanthopoulos said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX